EP3110848

REGENERON PHARMACEUTICALS, INC.
Application Number
EP15710650A
Filing Date
Feb 26, 2015
Status
Granted And Under Opposition
Jan 12, 2024
Grant Date
Feb 14, 2024
External Links
Slate, Register

Biblio Summary

The patent EP3110848B1 was granted on Feb 14, 2024 by Regeneron Pharmaceuticals, Inc. The patent is currently Granted And Under Opposition.

The table below shows 5 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

HAMPTON KNOWLES LIMITEDNov 14, 2024ADMISSIBLE
LUIGI, RUMINov 14, 2024ADMISSIBLE
BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBBNov 13, 2024ADMISSIBLE
DORRIES, HANS ULRICHNov 13, 2024ADMISSIBLE
SECERNA LLPNov 13, 2024ADMISSIBLE

The table below shows the patents of Regeneron Pharmaceuticals, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3515465Methods For Treating Severe Atopic Dermatitis By Administering An Il-4R InhibitorFeb 7, 20247
EP3973987Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistJan 10, 20246
EP4011915Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistNov 15, 20236